A team of Researchers are currently studying on a potential new avenue for the treatment of triple-negative breast cancer, which is a particularly aggressive breast cancer subtype.
                   
A new study is looking into ways of devising more effective, targeted treatments for triple-negative breast cancer.

             

A team of Researchers are currently studying on a potential new avenue for the treatment of triple-negative breast cancer,which is a particularly aggressive breast cancer subtype.


Research suggests that triple-negative breast cancer mostly affects Hispanic and African-American women, and it accounts for 10 to 20 percent of invasive breast cancer diagnoses.

What is Triple-negative breast cancer?

Triple-negative breast cancer is a type of breast cancer wherein the tumors do not express estrogen receptor, progesterone receptor, or the genes that promote the production of a protein called HER2, which plays a role in the growth of some cancer cells.


These receptors typically promote the growth of cancerous tumors, and most types of breast cancer test positive for one or more of these.

            

            

By contrast, triple-negative breast cancer, as its name suggests, tests negative for these receptors. This type of cancer is especially aggressive and does not respond to the usual breast cancer therapies.


These negative results mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, nor by the presence of too many HER2 receptors. Therefore, triple-negative breast cancer does not respond to hormonal therapy (such as tamoxifen or aromatase inhibitors) or therapies that target HER2 receptors, such as Herceptin (chemical name: trastuzumab). However, other medicines can be used to treat triple-negative breast cancer.


About 10-20% of breast cancers — more than one out of every 10 — are found to be triple-negative. For doctors and researchers,there is intense interest in finding new medications that can treat this kind of breast cancer. Early studies are trying to find out whether certain medications can interfere with the processes that cause triple-negative breast cancer to grow.

             

Research for finding new avenues for treating Triple-negative breast cancer

Anew study from the University of Freiburg in Germany is testing potential new avenues for the treatment of this type of cancer.


Dr.Jochen Maurer, from the Center for Translational Cell Research, and Dr. Roland Schüle, from the Center of Clinical Research - both based at the University of Freiburg - led groundbreaking research around cancer stem-like cells, which promote tumor growth and resilience.


Their teams developed a novel inhibitor for the epigenetic regulator KDM4, which is an enzyme that regulates gene expression and is implicated in the development of triple-negative breast cancer.

             

They hope that this might be the first step in devising a better, more targeted treatment for this aggressive type of cancer. The study's findings were reported in the journal Cancer Research.

The KDM4 inhibitor targets breast cancer stem-like cells

Much research has been conducted in an effort to understand what scientists term "cancer stem-like cells," which are cells that are very similar to normal stem cells in the body yet which promote cancerous activity.


Cancer stem-like cells are very adaptable, and they are often able to resist to the most invasive cancer therapies, thereby leading to the formation of new tumors and metastasis.


The researchers have now managed to isolate cancer stem-like cells from human breast cancer tumors. This allowed them to have a closer look at the mechanisms of these cells and how they promote cancerous growth.


Dr. Maurer and his colleagues managed to develop an in vitro model of cancer stem-like cells that faithfully corresponded to the ones extracted from the original triple-negative breast cancer tumors.


Theteams of Drs. Maurer and Schüle then collaborated in testing the effectiveness of various epigenetic inhibitors using their new cancer stem cell model.

             

Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa). KDM4s are co-activators of androgen receptor (AR) and are thus potential therapeutic targets.

             

Drs.Maurer and Schüle found that a newly developed inhibitor of the KDM4 enzyme exhibited promising effects in its action on cancer stem-like cells.


The researchers managed to stop several stem-like cell populations from proliferating, and, by using the KDM4 inhibitor, they also succeeded in determining the cells to modify their "stem" state,thus rendering them less prone to promoting cancer.


Additionally,the scientists tested the inhibitor on mice in which human breast cancer tumors had been grown. These experiments also yielded promising results, as the researchers were able to reduce the growth of the tumors in the animals.

Bottom Line

“Our findings validate a unique BCSC culture system for drug screening and offer preclinical proof of concept forKDM4 inhibition as a new strategy to treat triple-negative breast cancer.” Drs. Maurer and Schüle


If the scientists' further research continues to bring successful results, this will bode well for the future of triple-negative breast cancer treatment, which currently has poor long-term outcomes.

YOUR REACTION?


You may also like

Facebook Conversations



Disqus Conversations